American Type Culture Collection (ATCC) Logo American Type Culture Collection (ATCC) Logo 0
  • Quick Order
  • Careers
  • Support

NCI-H929 [H929]

CRL-3580

NCI-H929 [H929] cells are B lymphocytes isolated from a malignant effusion in a 62-year-old, White, female plasmacytoma myeloma patient. Use these cells in cancer and immunology research. This product is an ATCC manufactured and accessioned progeny of ATCC CRL-9068 cited in US Pat. No. 4,892,829.
Product category
Human cells
Product type
Cell model
Organism
Homo sapiens, human
Cell type
B lymphocyte
Morphology
lymphoblast
Tissue
Bone; Marrow
Disease
Plasmacytoma
Applications
Immune system disorder research
Immunology
Product format
Frozen
Storage conditions
Vapor phase of liquid nitrogen
Buy Now
Price: $844.00 ea
Discounts may be available for our fellow nonprofit organizations. Login to see your price.

Generally ships within 1-3 business days

Documentation

ATCC determines the biosafety level of a material based on our risk assessment as guided by the current edition of Biosafety in Microbiological and Biomedical Laboratories (BMBL), U.S. Department of Health and Human Services. It is your responsibility to understand the hazards associated with the material per your organization’s policies and procedures as well as any other applicable regulations as enforced by your local or national agencies.

ATCC highly recommends that appropriate personal protective equipment is always used when handling vials. For cultures that require storage in liquid nitrogen, it is important to note that some vials may leak when submersed in liquid nitrogen and will slowly fill with liquid nitrogen. Upon thawing, the conversion of the liquid nitrogen back to its gas phase may result in the vial exploding or blowing off its cap with dangerous force creating flying debris. Unless necessary, ATCC recommends that these cultures be stored in the vapor phase of liquid nitrogen rather than submersed in liquid nitrogen.

Detailed product information

Characteristics

Volume
1.0 mL
Growth properties
Suspension
Derivation
This cell line was established from a malignant effusion in a patient with myeloma.
Age
62 years
Ethnicity
White
Gender
Female
Clinical data
This cell line was established from a malignant effusion.
Karyotype
Near tetraploid. Most copies of chromosome 8 have the 8q+ abnormality.
Antigen expression
PCA-1; CD38 +
Genes expressed
PCA-1; CD38+
Expression markers
Transferrin
Isotype
IgA, kappa
Comments
The cells are positive for plasma cell antigen 1 (PCA-1), transferrin receptor, CD38 (T10), but are negative for HLA DR, CALLA and markers of early B cell development.
They are negative for Epstein-Barr virus nuclear antigen (EBNA).
The cells have a rearrangement of the c-myc proto oncogene and express c-myc RNA.
There is also an activated ras allele.

Handling information

Complete medium
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium (ATCC 30-2001). To make the complete growth medium, add the following components to the base medium: 2-mercaptoethanol to a final concentration of 0.05 mM; fetal bovine serum (FBS; ATCC 30-2020) to a final concentration of 10%.
Temperature
37°C
Atmosphere
95% Air, 5% CO2
Handling procedure

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C.  Storage at -70°C will result in loss of viability.

  1. Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water.  Thawing should be rapid (approximately 2 minutes).
  2. Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
  3. Transfer the vial contents to a centrifuge tube containing 9.0 ml complete culture medium and spin at approximately 125 x g for 5 to 7 minutes.
  4. Resuspend cell pellet with the recommended complete medium (see the specific batch information for the culture recommended dilution ratio) and dispense into a 25 cm2 or a 75 cm2 culture flask).   It is important to avoid excessive alkalinity of the medium during recovery of the cells.  It is suggested that, prior to the addition of the vial contents, the culture vessel containing the growth medium be placed into the incubator for at least 15 minutes to allow the medium to reach its normal pH (7.0 to 7.6).
  5. Incubate the culture at 37°C in a suitable incubator.  A 5% CO2 in air atmosphere is recommended if using the medium described on this product sheet.
Subculturing procedure
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 4 X 105 viable cells/mL. Corning® T-75 flasks (catalog #431464) are recommended for subculturing this product.
Interval: Maintain cultures at cell concentrations between 5 X 105 and 1 X 106 viable cells/mL.
Medium Renewal: 2 to 3 times per week
Reagents for cryopreservation
Complete growth medium supplemented with 5% (v/v) DMSO (ATCC 4-X)

Quality control specifications

Mycoplasma contamination
Not detected
STR profiling
Amelogenin: X
CSF1PO: 11
D13S317: 12
D16S539: 9,13
D5S818: 11,12
D7S820: 10,12
THO1: 9.3
TPOX: 8,11
vWA: 14,15

History

Deposited as
ATCC accessioned progeny of NCI-H929 [H929] (ATCC CRL-9068)
Depositors
ATCC

Legal disclaimers

Intended use
This product is intended for laboratory research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use.
Warranty

The product is provided 'AS IS' and the viability of ATCC® products is warranted for 30 days from the date of shipment, provided that the customer has stored and handled the product according to the information included on the product information sheet, website, and Certificate of Analysis. For living cultures, ATCC lists the media formulation and reagents that have been found to be effective for the product. While other unspecified media and reagents may also produce satisfactory results, a change in the ATCC and/or depositor-recommended protocols may affect the recovery, growth, and/or function of the product. If an alternative medium formulation or reagent is used, the ATCC warranty for viability is no longer valid.  Except as expressly set forth herein, no other warranties of any kind are provided, express or implied, including, but not limited to, any implied warranties of merchantability, fitness for a particular purpose, manufacture according to cGMP standards, typicality, safety, accuracy, and/or noninfringement.

Disclaimers

This product is intended for laboratory research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. Any proposed commercial use is prohibited without a license from ATCC.

While ATCC uses reasonable efforts to include accurate and up-to-date information on this product sheet, ATCC makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. ATCC does not warrant that such information has been confirmed to be accurate or complete and the customer bears the sole responsibility of confirming the accuracy and completeness of any such information.

This product is sent on the condition that the customer is responsible for and assumes all risk and responsibility in connection with the receipt, handling, storage, disposal, and use of the ATCC product including without limitation taking all appropriate safety and handling precautions to minimize health or environmental risk. As a condition of receiving the material, the customer agrees that any activity undertaken with the ATCC product and any progeny or modifications will be conducted in compliance with all applicable laws, regulations, and guidelines. This product is provided 'AS IS' with no representations or warranties whatsoever except as expressly set forth herein and in no event shall ATCC, its parents, subsidiaries, directors, officers, agents, employees, assigns, successors, and affiliates be liable for indirect, special, incidental, or consequential damages of any kind in connection with or arising out of the customer's use of the product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, ATCC is not liable for damages arising from the misidentification or misrepresentation of such materials.

Please see the material transfer agreement (MTA) for further details regarding the use of this product. The MTA is available at www.atcc.org.

Frequently Asked Questions

References

Curated Citations

Hollis GF, et al. Complex translocation disrupts c-myc regulation in a human plasma cell myeloma. Mol. Cell. Biol. 8: 124-129, 1988. PubMed: 3275865

Gazdar AF, et al. Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene. Blood 67: 1542-1549, 1986. PubMed: 2423157

Ernst TJ, et al. Identification of a second transforming gene, rasn, in a human multiple myeloma line with a rearranged c-myc allele. Blood 72: 1163-1167, 1988. PubMed: 3048435

Recent tests for IgA, kappa have not detected the production of IgA; the cells are producing kappa light chain.

For product-related inquiries and issues, contact Technical Service:

Message Us

Hours of Operation

Monday - Friday
9:00am - 5:00pm
US Eastern Time